Addressing current challenges in cancer immunotherapy with mathematical and computational modelling

被引:59
作者
Konstorum, Anna [1 ]
Vella, Anthony T. [2 ]
Adler, Adam J. [2 ]
Laubenbacher, Reinhard C. [1 ,3 ]
机构
[1] UConn Hlth, Ctr Quantitat Med, Farmington, CT 06030 USA
[2] UConn Hlth, Dept Immunol, Farmington, CT USA
[3] Jackson Lab Genom Med, Farmington, CT 06032 USA
基金
美国国家卫生研究院;
关键词
cancer immunotherapy; mathematical modelling; optimal control; MIXED IMMUNOTHERAPY; IMMUNE-RESPONSE; EFFICACY; CHEMOTHERAPY; ALGORITHM; IMMUNOPREVENTION; OPTIMIZATION; SIMULATION; PROTOCOLS; DISCOVERY;
D O I
10.1098/rsif.2017.0150
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The goal of cancer immunotherapy is to boost a patient's immune response to a tumour. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumour microenvironment, immune-modulating effects of conventional treatments and therapy-related toxicities. These complexities can be incorporated into mathematical and computational models of cancer immunotherapy that can then be used to aid in rational therapy design. In this review, we survey modelling approaches under the umbrella of the major challenges facing immunotherapy development, which encompass tumour classification, optimal treatment scheduling and combination therapy design. Although overlapping, each challenge has presented unique opportunities for modellers to make contributions using analytical and numerical analysis of model outcomes, as well as optimization algorithms. We discuss several examples of models that have grown in complexity as more biological information has become available, showcasing how model development is a dynamic process interlinked with the rapid advances in tumour-immune biology. We conclude the review with recommendations for modellers both with respect to methodology and biological direction that might help keep modellers at the forefront of cancer immunotherapy development.
引用
收藏
页数:10
相关论文
共 81 条
[1]   Autoimmunity associated with immunotherapy of cancer [J].
Amos, Sally M. ;
Duong, Connie P. M. ;
Westwood, Jennifer A. ;
Ritchie, David S. ;
Junghans, Richard P. ;
Darcy, Phillip K. ;
Kershaw, Michael H. .
BLOOD, 2011, 118 (03) :499-509
[2]   Predictive mathematical models of cancer signalling pathways [J].
Bachmann, J. ;
Raue, A. ;
Schilling, M. ;
Becker, V. ;
Timmer, J. ;
Klingmueller, U. .
JOURNAL OF INTERNAL MEDICINE, 2012, 271 (02) :155-165
[3]   A Mathematical Model to Elucidate Brain Tumor Abrogation by Immunotherapy with T11 Target Structure [J].
Banerjee, Sandip ;
Khajanchi, Subhas ;
Chaudhuri, Swapna .
PLOS ONE, 2015, 10 (05)
[4]  
BOCK E., 2016, CAR T-Cell Therapy Moves Closer to FDA Approval
[5]   Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network [J].
Brusic, V ;
Rudy, G ;
Honeyman, M ;
Hammer, J ;
Harrison, L .
BIOINFORMATICS, 1998, 14 (02) :121-130
[6]   Mathematical model of pulsed immunotherapy for superficial bladder cancer [J].
Bunimovich-Mendrazitsky, Svetlana ;
Byrne, Helen ;
Stone, Lewi .
BULLETIN OF MATHEMATICAL BIOLOGY, 2008, 70 (07) :2055-2076
[7]   Mathematical model of BCG immunotherapy in superficial bladder cancer [J].
Bunimovich-Mendrazitsky, Svetlana ;
Shochat, Eliezer ;
Stone, Lewi .
BULLETIN OF MATHEMATICAL BIOLOGY, 2007, 69 (06) :1847-1870
[8]  
Burden T, 2004, DISCRETE CONT DYN-B, V4, P135
[9]  
Byrne HM, 2004, DISCRETE CONT DYN-B, V4, P81
[10]   Determination of the optimal therapeutic protocols in cancer immunotherapy [J].
Cappuccio, Antonio ;
Castiglione, Filippo ;
Piccoli, Benedetto .
MATHEMATICAL BIOSCIENCES, 2007, 209 (01) :1-13